10.1161/01.CIR.102.10.1101
10.1161/CIRCULATIONAHA.111.026542
10.1016/j.amjcard.2004.09.014
10.1161/CIRCULATIONAHA.113.001258
10.1016/j.ahj.2012.11.010
10.1016/j.amjmed.2012.07.015
10.1001/archinte.166.13.1391
10.1161/CIRCULATIONAHA.113.004420
10.1016/j.amjmed.2010.07.023
Campeau, 1976, Letter: grading of angina pectoris, Circulation, 54, 522, 10.1161/circ.54.3.947585
10.1016/S0002-9149(02)02463-3
10.1001/jamainternmed.2013.12199
Grani C Senn O Bischof M Cippa PE Hauffe T Zimmerli L Battegay E Franzen D . Diagnostic performance of reproducible chest wall tenderness to rule out acute coronary syndrome in acute chest pain: a prospective diagnostic study. BMJ Open 2015;5:e007442
Devon HA Rosenfeld A Steffen AD Daya M . Sensitivity, specificity, and sex differences in symptoms reported on the 13-item acute coronary syndrome checklist. J Am Heart Assoc 2014;3:e000586
10.1016/j.amjcard.2005.09.073
10.1161/01.CIR.0000109696.92474.92
10.1373/clinchem.2009.134460
10.1161/CIRCULATIONAHA.112.100867
10.1373/clinchem.2009.128363
10.1016/j.ijcard.2013.06.049
Agewall, 2011, Troponin elevation in coronary vs, non-coronary disease. Eur Heart J, 32, 404
10.1001/archinternmed.2012.3698
10.1161/CIRCULATIONAHA.111.023937
10.1016/j.amjmed.2011.10.031
10.1016/j.jacc.2009.01.076
10.1016/j.jacc.2010.01.029
10.1016/j.amjcard.2014.01.436
10.1016/j.jacc.2013.04.011
10.1016/j.ahj.2013.03.014
10.1016/j.jacc.2011.06.026
10.1016/j.jacc.2014.03.017
10.1016/j.amjmed.2015.01.046
10.1016/S0140-6736(11)60310-3
10.1016/j.jacc.2012.02.035
10.1016/j.jacc.2013.02.078
10.1161/CIRCULATIONAHA.114.014245
10.1016/j.jacc.2005.03.076
10.1161/CIRCIMAGING.112.980797
10.1016/j.amjcard.2010.08.066
10.1016/j.echo.2011.09.002
10.1016/j.jacc.2005.11.059
10.1161/01.CIR.0000047527.11221.29
10.1161/CIRCULATIONAHA.107.740597
10.1161/CIRCULATIONAHA.108.816512
10.1007/s12350-013-9736-9
10.1007/s12350-011-9484-7
10.1007/s12350-012-9520-2
10.1016/j.jacc.2006.08.064
10.1016/j.jacc.2011.03.068
10.1016/j.jacc.2012.11.061
10.1001/archinte.163.19.2345
10.1136/bmj.38985.646481.55
Kaul, 2001, Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIB, PARAGON-A and GUSTO IIB Investigators. Platelet IIB/IIIA antagonism for the reduction of acute global organization network. J Am Coll Cardiol, 38, 64
10.1016/j.amjmed.2004.02.034
10.1016/S0735-1097(02)02970-4
10.1016/j.ahj.2013.04.010
Rubini Gimenez, 2014, Direct comparison of high-sensitivity-cardiac troponin I vs, T for the early diagnosis of acute myocardial infarction. Eur Heart J, 35, 2303
10.1371/journal.pone.0007947
10.1136/bmjopen-2013-004425
10.1016/j.ahj.2012.12.020
10.1016/j.jacc.2009.09.071
10.1016/j.ahj.2003.05.004
10.1161/CIRCULATIONAHA.111.071860
10.1161/01.CIR.0000145144.56673.59
10.1001/jamainternmed.2014.4491
10.1016/j.jacc.2009.09.076
10.1161/CIRCULATIONAHA.108.828541
10.1016/j.ahj.2011.04.007
10.1056/NEJM199712043372302
10.1056/NEJM199610313351802
10.1016/j.jacc.2008.12.053
10.1016/0167-5273(93)90024-B
10.1016/S0735-1097(02)01968-X
10.1161/CIRCULATIONAHA.114.014494
Borzak, 1998, Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina, TIMI 7 Investigators. Thrombin inhibition in myocardial ischemia. Am J Cardiol, 81, 678
10.1161/CIRCULATIONAHA.110.944603
Yusuf, 1988, Overview of results of randomized clinical trials in heart disease, I. Treatments following myocardial infarction. JAMA, 260, 2088
10.1016/j.ijcard.2012.10.050
10.1016/j.ahj.2011.01.006
10.1016/S0735-1097(85)80400-9
10.1016/0002-9149(86)90727-7
10.1016/0002-9149(87)90171-8
10.2165/00003495-199100422-00008
10.1016/j.amjmed.2007.04.016
10.1016/0140-6736(90)92336-G
Lewis, 1983, Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina, Results of a Veterans Administration cooperative study. N Engl J Med, 309, 396
10.1056/NEJM198810273191701
Cairns, 1985, Aspirin, sulfinpyrazone, or both in unstable angina, Results of a Canadian multicenter trial. N Engl J Med, 313, 1369
10.1016/S0140-6736(01)05701-4
10.1161/01.CIR.0000130846.46168.03
10.1016/j.jacc.2006.06.065
10.1016/j.jacc.2008.11.030
10.1016/S0140-6736(08)61845-0
10.1016/j.jacc.2010.04.008
10.1161/CIRCULATIONAHA.108.857722
10.1016/S0140-6736(08)60422-5
10.1161/CIRCULATIONAHA.109.912550
10.1161/CIRCULATIONAHA.113.002589
Storey, 2001, Open multicentre study of the P2 T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes, Thromb Haemost, 85, 401, 10.1055/s-0037-1615596
10.1016/S0140-6736(13)61615-3
10.1016/j.jacc.2010.07.012
10.1161/CIRCULATIONAHA.114.011320
10.1161/CIRCULATIONAHA.114.011319
10.1016/S0140-6736(13)61170-8
10.1016/j.jacc.2012.02.026
10.1016/S0140-6736(10)61273-1
10.1016/j.jacc.2007.12.056
10.1161/CIRCULATIONAHA.109.851949
10.1016/S0140-6736(12)60161-5
10.1001/archinte.166.17.1842
10.1016/S0140-6736(13)61720-1
10.1161/CIRCULATIONAHA.106.180944
10.1016/j.ejcts.2008.02.024
10.1016/j.jacc.2012.06.043
Feres, 2013, Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial, JAMA, 310, 2510
10.1161/CIRCULATIONAHA.111.059022
10.1161/CIRCULATIONAHA.111.071589
10.1016/j.jacc.2014.09.008
Schulz-Schupke, 2015, ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs, 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J, 36, 1252
10.1016/j.jacc.2014.11.008
10.1161/CIRCULATIONAHA.113.003303
10.1016/S0140-6736(14)60612-7
Roffi, 2002, Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes, Gradient of benefit related to the revascularization strategy. Eur Heart J, 23, 1441
10.1016/j.jacc.2009.05.025
10.1161/CIRCULATIONAHA.110.958041
10.1080/09537100500163226
10.1001/jama.295.13.joc60034
10.1016/j.jacc.2009.03.062
10.1016/j.jacc.2007.12.052
10.1161/CIRCULATIONAHA.111.019745
10.1016/S0140-6736(00)02324-2
Hassan, 1995, Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial, J Thromb Thrombolysis, 2, 245, 10.1007/BF01062717
10.1016/S0140-6736(07)60450-4
10.1001/jama.1996.03540100055028
10.1016/j.jacc.2004.02.051
10.1161/01.CIR.0000158485.70761.67
10.1161/01.CIR.0000139868.53594.24
10.1016/j.amjcard.2009.03.053
10.1016/j.jacc.2007.11.035
Dewilde WJ Janssen PW Kelder JC Verheugt FW De Smet BJ Adriaenssens T Vrolix M Brueren GB Vandendriessche T Van Mieghem C Cornelis K Vos J Breet NJ ten Berg JM . Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention 2015 Mar 5;10 (11). pii: 20140202-08. doi:10.4244/EIJY14M06_07. [Epub ahead of print]
10.1016/j.amjcard.2012.02.045
10.1001/archinternmed.2010.271
10.1161/CIRCINTERVENTIONS.111.965186
10.1161/CIRCULATIONAHA.112.097014
10.1016/j.jacc.2014.11.053
10.1016/S0140-6736(12)62177-1
10.1016/j.jacc.2015.02.050
10.1161/CIRCULATIONAHA.112.114967
10.1016/j.jacc.2013.05.029
Sie, 2011, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors, Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis, 104, 669
10.1016/S0140-6736(15)60292-6
Di Minno, 1983, Monitoring the entry of new platelets into the circulation after ingestion of aspirin, Blood, 61, 1081, 10.1182/blood.V61.6.1081.1081
10.1111/j.1538-7836.2006.02245.x
10.1592/phco.20.15.1159.34585
10.1097/00001721-200101000-00002
Ageno, 2002, Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial, Thromb Haemost, 88, 48, 10.1055/s-0037-1613152
10.1016/j.jacc.2005.05.022
10.7326/0003-4819-150-5-200903030-00005
10.1016/S0140-6736(00)03125-1
10.1007/s40262-013-0049-6
10.1161/CIRCULATIONAHA.111.029017
10.1016/j.jcin.2010.10.011
10.1016/j.ahj.2013.07.006
10.1161/CIRCULATIONAHA.110.009449
10.1161/CIRCULATIONAHA.111.060871
10.1007/s11239-014-1084-3
10.1007/s11886-011-0192-3
10.1016/j.jacc.2007.10.040
10.1016/S0195-668X(03)00485-8
10.1161/CIRCINTERVENTIONS.113.000433
10.1001/jamasurg.2013.1560
10.1016/j.jacc.2010.10.029
10.1161/CIRCOUTCOMES.109.858811
10.1016/j.athoracsur.2013.07.020
10.1016/j.athoracsur.2012.07.086
10.1016/j.athoracsur.2011.03.105
10.1097/ACO.0b013e32831a40a3
10.1016/j.jcin.2009.05.004
10.1016/j.jacc.2013.11.029
Carson, 2012, Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion, Cochrane Database Syst Rev, 4, CD002042
10.7326/0003-4819-159-11-201312030-00007
10.1001/2013.jamainternmed.1001
10.1016/j.amjcard.2011.06.014
10.1016/j.ahj.2008.01.009
10.1016/S0735-1097(02)01770-9
10.1016/S0735-1097(85)80384-3
10.1056/NEJM200009283431303
10.1161/ATVBAHA.108.179705
10.1016/j.jacc.2005.10.065
10.1016/j.ahj.2013.10.011
10.1016/j.jacc.2007.04.086
10.1016/j.jacc.2006.10.054
10.1016/j.jelectrocard.2011.04.005
10.1016/j.jacc.2011.06.046
10.1016/j.ijcard.2011.09.032
10.1016/j.jacc.2006.06.050
10.1016/j.jacc.2010.03.007
10.7326/0003-4819-158-4-201302190-00006
10.1016/j.jacc.2009.11.063
10.1161/CIR.0b013e3181ec61df
10.1016/j.jacc.2014.02.586
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297–1309.
Williams, 2010, Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality, Cathet Cardiovasc Interv, 75, 886, 10.1002/ccd.22431
10.1007/s12350-008-9015-3
Bellandi, 2012, [Epidemiology of Tako-Tsubo cardiomyopathy: the Tuscany registry for Tako-Tsubo cardiomyopathy ], G Ital Cardiol (Rome), 13, 59
10.1016/j.amjcard.2013.04.010
10.1007/s00059-010-3339-x
10.1016/j.jacc.2008.04.050
10.1016/S0140-6736(97)07329-7
10.1016/S0140-6736(12)61223-9
10.1016/j.jcin.2013.09.008
10.1016/S0140-6736(11)60404-2
10.1016/j.jcin.2014.04.007
10.1056/NEJM200106213442501
10.1016/S0140-6736(02)09894-X
10.1016/S0140-6736(00)02427-2
10.1161/CIRCULATIONAHA.113.001803
10.1016/j.jacc.2012.03.010
10.1016/j.jacc.2009.04.076
10.1016/j.amjcard.2011.04.005
10.1136/bmjopen-2013-004052
10.1016/j.jtcvs.2012.05.043
10.1016/j.jtcvs.2007.10.042
10.1016/j.ahj.2010.01.002
10.1016/j.jcin.2010.01.012
10.1136/bmj.327.7427.1309
Gavaghan, 1991, Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery, A placebo-controlled, randomized study. Circulation, 83, 1526
10.1016/j.jtcvs.2012.04.004
10.1016/j.jtcvs.2011.01.069
10.1161/CIRCINTERVENTIONS.111.967208
Rastan, 2006, Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies, Circulation, 114, I477, 10.1161/CIRCULATIONAHA.105.001545
10.1016/j.jcin.2010.06.017
10.1016/j.ijcard.2013.09.003
10.1016/j.jtcvs.2005.08.059
10.1016/S0140-6736(09)60552-3
10.1016/S0140-6736(13)60141-5
10.1016/j.jacc.2011.02.032
10.1016/S0735-1097(00)00814-7
10.1161/01.CIR.100.20.2067
10.7326/0003-4819-131-1-199907060-00010
10.1016/S0140-6736(13)61782-1
Greenhalgh J Hockenhull J Rao N Dundar Y Dickson RC Bagust A . Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010;5:CD004587
10.1161/CIRCULATIONAHA.108.826479
10.1016/j.jacc.2004.10.074
10.1001/archinte.167.10.1009
10.1016/j.ahj.2011.09.025
10.1016/j.ijcard.2013.12.010
10.1016/j.jacc.2013.12.032
10.1056/NEJM199907223410402
10.1161/01.CIR.0000109491.66226.26
10.1161/CIRCULATIONAHA.106.620815
10.1161/CIRCULATIONAHA.108.789800
10.1001/archinternmed.2009.332
10.1016/S0195-668X(03)00320-8
10.1016/j.jacc.2004.11.055
Gale, 2012, Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes, The myocardial ischaemia national audit project 2003-2010. Eur Heart J, 33, 630
10.1161/CIRCULATIONAHA.107.182615
10.1016/j.jacc.2007.01.066
10.1136/bmjopen-2011-000540
10.7326/0003-4819-141-3-200408030-00007
10.1016/j.jcin.2012.06.008
Andreotti F Rocca B Husted S Ajjan RA Ten Berg J Cattaneo M Collet JP De Caterina R Fox KA Halvorsen S Huber K Hylek EM Lip GY Montalescot G Morais J Patrono C Verheugt FW Wallentin L Weiss TW Storey RF . Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015 Jul 9; doi:10.1093/eurheartj/ehv304 [Epub ahead of print].
10.1016/j.jacc.2013.09.070
10.1161/CIRCULATIONAHA.111.025452
10.1016/j.ahj.2013.01.005
10.1016/j.amjcard.2005.03.076
10.1016/S0140-6736(02)09089-X
Dotevall, 2005, Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes, Data from the Euro Heart Survey ACS. Diabet Med, 22, 1542
10.1161/CIRCULATIONAHA.109.913376
10.1016/j.ehj.2004.09.021
10.1016/j.diabet.2011.11.003
10.1016/j.jacc.2009.10.014
10.1161/CIRCULATIONAHA.108.791061
10.1016/j.jacc.2012.02.059
10.1016/j.ehj.2003.10.027
10.1016/S2213-8587(13)70089-5
10.1016/j.jacc.2004.06.072
Szummer, 2010, Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register, J Intern Med, 268, 40, 10.1111/j.1365-2796.2009.02204.x
10.1161/CIRCULATIONAHA.108.838169
10.1161/CIRCULATIONAHA.109.933796
10.2165/00129784-200505050-00002
10.1161/CIRCULATIONAHA.111.084996
10.1111/j.1365-2125.2010.03753.x
Collet, 2005, Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes, The Global Registry of Acute Coronary Events. Eur Heart J, 26, 2285
10.7326/0003-4819-147-5-200709040-00005
10.1016/j.jacc.2006.06.047
10.1161/CIRCINTERVENTIONS.111.961391
10.1161/CIRCULATIONAHA.106.671644
10.1016/j.jacc.2011.06.056
10.1371/journal.pone.0015070
10.1161/CIRCULATIONAHA.109.865352
10.1016/j.cjca.2011.04.004
10.1161/01.CIR.0000109691.16944.DA
10.1161/CIRCRESAHA.113.300268
10.1016/S0140-6736(13)61783-3
10.1016/j.healun.2011.12.001
10.1016/j.jtcvs.2012.05.044
10.1056/NEJM199908263410901
10.1111/j.1525-1594.2011.01408.x
10.1056/NEJM199209033271001
10.1016/S0140-6736(03)14284-5
10.1056/NEJM199108013250501
10.1016/S0140-6736(00)04560-8
10.1016/S0140-6736(98)11181-9
10.1056/NEJM200105313442201
10.1016/S0140-6736(99)04440-2
Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized aldactone evaluation study investigators. N Engl J Med, 341, 709
10.1111/j.1540-8167.2008.01191.x
10.1111/j.1540-8167.2011.02096.x
10.1016/j.ijcard.2014.03.113
10.1161/CIRCULATIONAHA.113.006286
Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003
Echt, 1991, Mortality and morbidity in patients receiving encainide, flecainide, or placebo, The Cardiac Arrhythmia Suppression Trial. N Engl J Med, 324, 781
10.1016/j.amjcard.2011.09.046
10.1016/j.jacc.2004.04.034
10.1161/01.CIR.99.22.2892
10.1161/01.CIR.0000127867.41621.85
10.1016/j.amjcard.2008.08.055
10.1016/j.ahj.2014.04.010
10.1182/asheducation-2010.1.135
Tempelhof, 2012, Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty, Tex Heart Inst J, 39, 86
10.1016/j.tmrv.2013.05.005
10.1053/j.seminhematol.2010.04.001
10.1056/NEJM200104263441704
Patrignani, 2015, Cyclooxygenase inhibitors: from pharmacology to clinical read-outs, Biochim Biophys Acta, 1851, 422, 10.1016/j.bbalip.2014.09.016
10.1161/CIRCULATIONAHA.113.004480
10.1016/S0140-6736(13)60900-9
10.7326/0003-4819-154-8-201104190-00003
10.1161/CIRCULATIONAHA.109.891523
10.1001/jama.1982.03320370021023
10.1016/S0735-1097(96)00489-5
10.1056/NEJM199808203390801
10.1016/S0140-6736(10)61350-5
Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342, 145
10.1016/j.ijcard.2014.11.107
10.7326/0003-4819-143-9-200511010-00010
10.1161/CIRCULATIONAHA.104.503995
10.1016/S0140-6736(03)14286-9
10.1016/S0140-6736(98)04311-6
10.1016/j.amjmed.2004.01.009
10.1097/00149831-200606000-00012
10.1161/CIRCULATIONAHA.109.876383
Heran, 2011, Exercise-based cardiac rehabilitation for coronary heart disease, Cochrane Database Syst Rev, 1, CD001800
10.1016/S0140-6736(04)16980-8
10.1097/HJH.0b013e32832aa6b5
Nallamothu, 2007, Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention, The Global Registry of Acute Coronary Events. Heart, 93, 1552
10.1161/01.CIR.0000112577.69066.CB
